Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
22 Aprile 2024 - 2:00PM
Business Wire
Demonstrates commitment to generating
real-world clinical evidence to change disease management and
improve patient outcomes
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA
(cfDNA) and genetic testing, today announced that it has passed a
significant milestone with the publication of more than 200
peer-reviewed papers highlighting Natera’s technology in the
scientific literature.
Landmark cutting-edge science and clinical trial data based on
Natera’s suite of products have been published in top journals,
such as Science, Nature, Nature Medicine, and New England Journal
of Medicine (NEJM). This includes:
- More than 85 publications featuring Natera’s women’s health
products, including data from SMART, the largest prospective NIPT
study ever performed, with over 18,000 patients and confirmed
genetic outcomes collected for all samples included in the
analysis;
- More than 75 publications featuring Natera’s oncology products,
including data from the GALAXY arm of the ongoing CIRCULATE-Japan
trial, one of the largest and most comprehensive prospective
studies of molecular residual disease testing in colorectal cancer;
and
- Approximately 40 publications featuring Natera’s organ health
products, including data from ProActive, the largest prospective
donor-derived cfDNA study in kidney transplantation, and data from
RenaCARE, a large, multisite, real-world, prospective study
assessing the frequency and impact of genetic testing in chronic
kidney disease.
“When it comes to transforming patient care, high-quality
science and data drive everything,” said Alexey Aleshin, M.D.,
chief medical officer & general manager of oncology at Natera.
“We have been very deliberate in making investments over the years
to develop tests based on cutting-edge science – including some of
the largest and most impactful studies ever to be performed in our
field. We remain committed to generating evidence that supports the
real-world impact of our innovations.”
About Natera Natera™ is a global leader in cell-free DNA
and genetic testing, dedicated to oncology, women’s health, and
organ health. We aim to make personalized genetic testing and
diagnostics part of the standard-of-care to protect health and
inform earlier, more targeted interventions that help lead to
longer, healthier lives. Natera’s tests are supported by more than
200 peer-reviewed publications that demonstrate excellent
performance. Natera operates ISO 13485-certified and CAP-accredited
laboratories certified under the Clinical Laboratory Improvement
Amendments (CLIA) in Austin, Texas, and San Carlos, California. For
more information, visit www.natera.com.
Forward-Looking Statements All statements other than
statements of historical facts contained in this press release are
forward-looking statements and are not a representation that
Natera’s plans, estimates, or expectations will be achieved. These
forward-looking statements represent Natera’s expectations as of
the date of this press release, and Natera disclaims any obligation
to update the forward-looking statements. These forward-looking
statements are subject to known and unknown risks and uncertainties
that may cause actual results to differ materially, including with
respect to whether the results of clinical or other studies will
support the use of our product offerings, the impact of results of
such studies, or our expectations of the benefits of our tests and
product offerings to patients, providers, and payers. Additional
risks and uncertainties are discussed in greater detail in "Risk
Factors" in Natera’s recent filings on Forms 10-K and 10-Q and in
other filings Natera makes with the SEC from time to time. These
documents are available at www.natera.com/investors and
www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240422167869/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc.,
510-826-2350, investor@natera.com Media: Lesley Bogdanow, VP of
Corporate Communications, Natera, Inc., pr@natera.com
Grafico Azioni Natera (NASDAQ:NTRA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Natera (NASDAQ:NTRA)
Storico
Da Giu 2023 a Giu 2024